News

Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Indianapolis Business Journal1h
Prices for obesity drugs fall, but affordability still out of reach for many
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even ...
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share
By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...
Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Pulmonology Advisor4d
Knockoff Wegovy Concerns End Partnership Between Novo Nordisk and Hims & Hers
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
How Novo Nordisk misread the US market for its weight loss sensation
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.